09:16 AM EDT, 07/19/2024 (MT Newswires) -- Clearmind Medicine ( CMND ) said Friday that it has partnered with advisory firm JS First to identify global manufacturers and distributors to develop alcohol substitute beverages using 5-Methoxy-2-Aminoindane, or MEAI.

The company said the collaboration will see JS First studying manufacturing and licensing alternatives, as well as identifying potential partners in regions such as the US, Europe, Africa, and Southeast Asia.

This comes after Clearmind's recent patent approvals in the US, India, and Europe for their MEAI-based non-alcoholic beverage, the company said.

Shares of the company were up nearly 3% in recent Friday premarket activity.

Price: 1.7600, Change: +0.05, Percent Change: +2.92